Form 4: BioCorRx Director Harsha Murthy Reports Acquisition of Common Stock
SEC Form 4 Filing
Director Harsha Murthy reports acquiring shares of BioCorRx Inc. as part of a director agreement.
Summary
- Harsha Murthy, a director of BioCorRx Inc., filed a Form 4 detailing changes in beneficial ownership.
- On January 2, 2024, Murthy acquired 6,173 shares of common stock at $0 as compensation for his services as a director.
- On March 28, 2024, Murthy acquired 5,566 shares of common stock at $0 as compensation for his services as a director.
- These shares were issued pursuant to a Director Agreement dated January 20, 2023.
- The agreement stipulates that Murthy receives shares equivalent to $5,000 per fiscal quarter, based on the average closing price of the company's stock in the three trading days before the end of the quarter.
- Following these transactions, Murthy directly owns 19,719 shares of BioCorRx Inc. common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the document simply reports stock acquisitions by a director as part of a pre-existing compensation agreement. It doesn't inherently indicate positive or negative prospects for the company.
Positives
- The director's continued compensation in stock aligns his interests with those of the shareholders.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Comparison to Industry Standards
- Director compensation through stock grants is a common practice among publicly traded companies, particularly in smaller firms like BioCorRx, to conserve cash and align director interests with shareholder value.
- The specifics of the Director Agreement, such as the quarterly grant value ($5,000) and the valuation method (average closing price over three days), are typical components of such agreements.
Related Party Transactions
- The issuance of shares to Harsha Murthy under the Director Agreement constitutes a related party transaction.
Stakeholder Impact
- The stock issuance could slightly dilute existing shareholders' equity.
Key Dates
| Date | Description |
|---|---|
| 2023-01-20 | Date of the Director Agreement between BioCorRx Inc. and Harsha Murthy. |
| 2024-01-02 | Date of transaction where Harsha Murthy acquired 6,173 shares of common stock. |
| 2024-03-28 | Date of transaction where Harsha Murthy acquired 5,566 shares of common stock. |
| 2024-04-03 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Director Compensation, Common Stock, BioCorRx, Murthy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.